In dual diagnosis populations, prescribing is both essential and high-risk. People may have multiple prescribers, variable adherence, substance interactions, and rapid changes in presentation driven by intoxication or withdrawal. Transitions—ED visits, detox episodes, short inpatient stays—are common, and each transition increases the chance of medication discrepancies and unsafe combinations. When medication governance is weak, systems see predictable outcomes: sedation-related falls, overdose risk, destabilization, repeat crises, and avoidable ED use. This article sets out practical medication safety and prescribing governance for dual diagnosis services, focused on day-to-day workflows and auditable controls. For related resources, see Dual Diagnosis & Co-Occurring Conditions and Mental Health Service Models.
Why medication governance fails in co-occurring care
Prescribing risk is often framed as an individual clinician issue, but the dominant causes are system-level: unclear prescriber-of-record, incomplete reconciliation after transitions, poor communication to the wider team, and lack of follow-up after medication changes. Co-occurring conditions also distort clinical signals—sleep disturbance may be withdrawal, side effects, or mood instability—so monitoring must be structured rather than impressionistic.
A psychologically informed approach assumes that fear of stigma and fear of consequences can reduce disclosure about substance use. Medication governance must therefore be designed to be non-punitive and engagement-oriented while still managing safety risk rigorously.
Two explicit expectations you should design for
Expectation 1: Reliable medication reconciliation after every transition of care
Funders and oversight bodies commonly expect providers to demonstrate medication reconciliation after high-risk transitions such as ED visits, detox, and inpatient discharge. This is a patient safety standard in spirit even when operationalized differently across settings. The expectation is clear: medication lists are accurate, changes are understood, and the plan for access and monitoring is explicit.
Expectation 2: Auditable monitoring and follow-up after medication changes in high-risk cohorts
In dual diagnosis care, “prescribed” is not the same as “taken.” Oversight partners increasingly expect evidence that providers monitor adherence barriers, side effects, sedation risk, and symptom change after adjustments—especially when substance use increases risk. Follow-up windows and escalation routes must be defined and documented.
Operational Example 1: Prescriber-of-record and reconciliation workflow that prevents duplication and unsafe combinations
What happens in day-to-day delivery
The service assigns a prescriber-of-record for each client (or a prescribing team) and documents this clearly in the record and care plan. At intake and after any external care episode, staff complete medication reconciliation with the client: current meds, recent changes, adherence patterns, and where prescriptions are filled. The reconciliation is verified using available sources (discharge summaries, pharmacy lists, client medication bottles, collateral information with consent). A standard reconciliation note is created that includes: confirmed list, changes made, reasons, and key risks to monitor.
The reconciled medication plan is then communicated to the multidisciplinary team via a brief “medication snapshot” field: what to watch for, what the client agreed, and when follow-up is scheduled. Case managers and peers receive clear guidance on what to reinforce (e.g., appointment timing, refill process) without making them responsible for clinical decisions beyond role.
Why the practice exists (failure mode it addresses)
The failure mode is fragmented prescribing: multiple clinicians prescribe without awareness of each other, medication lists diverge, and clients inadvertently take dangerous combinations or stop meds abruptly. Another failure is post-transition discrepancy—detox or ED changes meds, but the outpatient team continues the old plan. The prescriber-of-record and reconciliation workflow exists to produce one coherent, current medication plan.
What goes wrong if it is absent
Without clear prescribing ownership and reconciliation, clients may receive overlapping sedatives, inconsistent antidepressant regimens, or medication changes that are never monitored. Substance use can amplify side effects and risk, increasing overdose or fall risk. Teams misinterpret side effects as psychiatric deterioration and may escalate unnecessarily. Operationally, adverse events rise, ED presentations increase, and investigations are difficult because there is no single accountable medication narrative.
What observable outcome it produces
Evidence includes fewer medication discrepancies after transitions, reduced duplication of prescriptions, and clearer team coordination. Audit artifacts include reconciliation records completed within defined windows after ED/inpatient episodes, documented prescriber-of-record assignment, and fewer incident reports linked to medication confusion.
Operational Example 2: Follow-up-after-change protocol with risk-based timing and escalation
What happens in day-to-day delivery
Any medication change triggers a follow-up protocol that is risk-based. For higher-risk changes (new sedating medication, dose increases, MAT initiation, antipsychotic changes), the service schedules a check-in within 3–7 days, with earlier contact if the client has overdose history or unstable housing. The check-in covers: adherence, side effects (including sedation), substance use changes, and symptom trajectory. Staff use a structured template so monitoring is consistent and auditable. If concerns arise, escalation routes are clear: same-day prescriber review, coordination with medical providers, or step-up support such as additional visits and peer outreach.
The follow-up also includes practical barriers: pharmacy access, cost, transportation, and whether the client understands the regimen. These are documented as operational tasks (e.g., “arrange delivery,” “resolve prior authorization”) with named owners.
Why the practice exists (failure mode it addresses)
The failure mode is “change and hope.” In co-occurring conditions, side effects, relapse, and adherence problems often emerge quickly, and missed follow-up can lead to rapid deterioration. The protocol exists to detect early problems, prevent avoidable harm, and keep the client engaged rather than abandoning them to manage complexity alone.
What goes wrong if it is absent
Without structured follow-up, clients may stop meds abruptly, combine substances to manage side effects, or experience sedation that increases overdose and injury risk. Psychiatric symptoms may worsen unnoticed until a crisis occurs. Operationally, the system sees repeat crises soon after prescribing events and cannot demonstrate that it managed medication risk responsibly.
What observable outcome it produces
Evidence includes higher follow-up completion rates after medication changes, reduced medication-related crisis episodes, and improved adherence outcomes. Audit trails show documented check-ins, escalation actions when concerns are identified, and resolution of pharmacy barriers within defined timeframes.
Operational Example 3: Medication access assurance and continuity during high-risk transitions
What happens in day-to-day delivery
For clients leaving detox, ED, or inpatient care, the service runs a “first 7 days” medication continuity assurance. A coordinator confirms the discharge medication plan, ensures prescriptions are transmitted, and verifies that the client can obtain medications promptly. Where clients lack phone access or stable storage, the plan includes realistic solutions: pickup at a partner clinic, shelter medication storage coordination, or pharmacy delivery where feasible. The service confirms medication acquisition within 24–72 hours for higher-risk individuals and documents the confirmation method.
If prescriptions cannot be filled (prior authorization delays, cost barriers, pharmacy stock issues), the coordinator escalates rapidly to the prescriber-of-record to adjust the plan or arrange alternatives. This prevents predictable medication gaps from becoming relapse or crisis drivers.
Why the practice exists (failure mode it addresses)
The failure mode is post-transition medication gap. Co-occurring conditions make these gaps particularly dangerous because withdrawal, relapse risk, and psychiatric instability can converge. The continuity assurance workflow exists to make discharge clinically meaningful and to prevent avoidable crisis recurrence.
What goes wrong if it is absent
Absent continuity assurance, clients may go days without medications, leading to withdrawal, rebound symptoms, or relapse. They return to ED or crisis lines, and the system labels them “non-adherent,” masking the real access failure. Operationally, readmissions and crisis utilization increase, and providers struggle to show impact despite significant investment.
What observable outcome it produces
Evidence includes improved prescription fill rates post-discharge, reduced medication-related ED returns, and fewer crisis episodes in the first 30 days after transitions. Audit artifacts include continuity checks, barrier-resolution logs, and documentation of escalations when prescriptions cannot be filled.
Governance and assurance: how leaders make prescribing safety defensible
A strong governance model includes: monthly reconciliation compliance reporting, sampling of medication follow-up notes after changes, monitoring of medication-related incidents, and review of post-transition continuity outcomes. Leaders should also track whether prescribing decisions are integrated with the wider care plan—especially safety planning and relapse prevention. When prescribing governance is structured and auditable, dual diagnosis services reduce avoidable harm and improve continuity outcomes that systems and commissioners can trust.